ReviewBiomolecules2023
Complement as a Biomarker for Systemic Lupus Erythematosus.
Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- Variants in the interferon regulatory factor 5 gene confer genetic risk for systemic lupus erythematosus in a Han Chinese population.Annals of medicine · 2026Article
- Macrophage pyroptosis in lupus nephritis - Novel insights into renal pathogenesis and clinical correlates: A cross-sectional study.Medicine · 2026Observational
- Prolonged serologically active clinically quiescent systemic lupus erythematosus: a longitudinal study on the role of IgG anti-dsDNA and C3.Rheumatology (Oxford, England) · 2026Article
- Sera of Healthy First-Degree Relatives of SLE Patients Contain Autoantibodies to Globular Domains of C1q.Antibodies (Basel, Switzerland) · 2026Article
- Clinical outcomes and prognostic factors in lupus nephritis: impact of remission on renal and overall survival in a single-center study.BMC nephrology · 2026Article
- Association Between Nutritional Status, Body Composition, and Disease Activity in Systemic Lupus Erythematosus: An Exploratory Retrospective Study.Diseases (Basel, Switzerland) · 2026Article
- Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Immunopathogenesis of neuropsychiatric systemic lupus erythematosus: current insights into inflammatory and thrombotic pathways.Journal of neuroinflammation · 2026Review
- Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.Biomedicines · 2026Article
- Detection of white matter microstructural changes in patients with systemic lupus erythematosus based on multiple diffusion models and related diffusion metrics.Neural regeneration research · 2026Article
- GRN and KLRB1 define a shared peripheral-blood transcriptomic signature linking SLE and IPF.Journal of translational autoimmunity · 2026Article
- Optic nerve head microcirculation on optical coherence tomography angiography is reduced in systemic lupus erythematosus and relates to nailfold videocapillaroscopy phenotypes: a cross-sectional case-control study.Clinical rheumatology · 2026Article
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
- Article
- The interaction of fibrinolysis and the complement system in patients with acute pulmonary embolism, treated with ultrasound-assisted catheter-directed thrombolysis.Thrombosis journal · 2026Article
- Regional variation in serum ficolin levels and their association with disease activity and clinical manifestations in systemic lupus erythematosus (SLE) patients from India.Immunologic research · 2026Article
- Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study.Frontiers in immunology · 2026Article
- Reduced C3 Levels Link Dyslipidemia and Renal Involvement in Systemic Lupus Erythematosus.Journal of inflammation research · 2026Article
- Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products and cell-bound complement activation products, are considered to be more sensitive than traditional complement markers, such as serum C3 and C4 levels and total complement activity (CH50), which become more widely used. In this review, we report the complement testing in the management of SLE over the last decade and summarize their utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.